Maravai LifeSciences Holdings, Inc.
Symbol: MRVI
NASDAQ
9.86
USDTrhová cena dnes
-9.9573
Pomer P/E
-0.0063
Pomer PEG
2.48B
MRK Cap
- 0.00%
Výnos DIV
Maravai LifeSciences Holdings, Inc. (MRVI) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2296.43 | 575 | 632.1 | 551.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 200.74 | 55.7 | 146.8 | 117.5 | ||||||
balance-sheet.row.inventory | 197.79 | 51.4 | 43.2 | 51.6 | ||||||
balance-sheet.row.other-current-assets | 73.01 | 17.8 | 25.8 | 19.7 | ||||||
balance-sheet.row.total-current-assets | 2767.97 | 699.9 | 847.9 | 740 | ||||||
balance-sheet.row.property-plant-equipment-net | 807.33 | 222.6 | 116.6 | 46.3 | ||||||
balance-sheet.row.goodwill | 1304.55 | 326 | 283.7 | 152.8 | ||||||
balance-sheet.row.intangible-assets | 897.69 | 221 | 216.7 | 117.6 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 2202.23 | 547 | 500.3 | 270.3 | ||||||
balance-sheet.row.long-term-investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.tax-assets | 1764.23 | 0 | 765.8 | 808.1 | ||||||
balance-sheet.row.other-non-current-assets | -113.5 | 9.3 | 40.3 | 52.9 | ||||||
balance-sheet.row.total-non-current-assets | 4696.11 | 787.5 | 1434.4 | 1178.2 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.account-payables | 35.04 | 10.7 | 6 | 8.2 | ||||||
balance-sheet.row.short-term-debt | 45.01 | 12.9 | 11.7 | 9.7 | ||||||
balance-sheet.row.tax-payables | 1 | 1 | 1 | 1.4 | ||||||
balance-sheet.row.long-term-debt-total | 2192.18 | 518.7 | 573.6 | 524.6 | ||||||
Deferred Revenue Non Current | 829.37 | 79.4 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 21.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 209.03 | 60.5 | 89.4 | 65.7 | ||||||
balance-sheet.row.total-non-current-liabilities | 3807.23 | 610.1 | 1266.9 | 1279.1 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 285.32 | 79.4 | 57.8 | 3.7 | ||||||
balance-sheet.row.total-liab | 4106.89 | 697.6 | 1377.1 | 1372.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 10.05 | 2.5 | 2.6 | 2.6 | ||||||
balance-sheet.row.retained-earnings | 1349.25 | 285.7 | 404.8 | 184.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.other-total-stockholders-equity | 507.98 | 128.5 | 137.9 | 128.4 | ||||||
balance-sheet.row.total-stockholders-equity | 1867.28 | 416.8 | 545.2 | 315.5 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.minority-interest | 1489.91 | 373.1 | 360 | 229.9 | ||||||
balance-sheet.row.total-equity | 3357.19 | 789.9 | 905.2 | 545.4 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 7464.08 | - | - | - | ||||||
Total Investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.total-debt | 2398.63 | 611 | 585.3 | 534.3 | ||||||
balance-sheet.row.net-debt | 102.2 | 36 | -46.9 | -17 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -147.04 | -119 | 490.7 | 469.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.53 | 48.8 | 38.1 | 24.8 | ||||||
cash-flows.row.deferred-income-tax | 756.46 | 754.9 | 42.3 | 46.9 | ||||||
cash-flows.row.stock-based-compensation | 40.66 | 34.6 | 18.7 | 10.5 | ||||||
cash-flows.row.change-in-working-capital | 29.5 | 97.8 | -45.1 | -176.6 | ||||||
cash-flows.row.account-receivables | 19.87 | 84.4 | -22.3 | -70.4 | ||||||
cash-flows.row.inventory | 4.85 | 0.6 | 9.5 | -21.6 | ||||||
cash-flows.row.account-payables | 1.84 | 5.3 | -1.6 | 0.7 | ||||||
cash-flows.row.other-working-capital | 17.96 | 7.5 | -30.7 | -85.3 | ||||||
cash-flows.row.other-non-cash-items | -686.93 | -690.9 | -8.7 | -6.2 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 32.68 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.acquisitions-net | 75.02 | -69.6 | -238.3 | 120 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | 6.42 | 12.9 | -12.2 | 0.5 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -56.82 | -122.3 | -267.6 | 105.7 | ||||||
cash-flows.row.debt-repayment | -5.92 | -5.8 | -13.9 | -6 | ||||||
cash-flows.row.common-stock-issued | -1.45 | 0 | 2.4 | 1.7 | ||||||
cash-flows.row.common-stock-repurchased | -0.35 | 0 | 0 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-financing-activites | -35.07 | -55.3 | -176 | -154.8 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -42.44 | -61.1 | -187.5 | -159 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1.6 | 0 | -0.1 | ||||||
cash-flows.row.net-change-in-cash | -66.58 | -57.2 | 80.9 | 315.1 | ||||||
cash-flows.row.cash-at-end-of-period | 2296.43 | 575 | 632.1 | 551.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 2363.02 | 632.1 | 551.3 | 236.2 | ||||||
cash-flows.row.operating-cash-flow | 32.68 | 126.2 | 536 | 368.6 | ||||||
cash-flows.row.capital-expenditure | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.free-cash-flow | -30.67 | 60.7 | 518.9 | 353.7 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 274.1 | 288.9 | 883 | 799.2 | ||||||
income-statement-row.row.cost-of-revenue | 154 | 151.3 | 169 | 140.6 | ||||||
income-statement-row.row.gross-profit | 120.1 | 137.6 | 714 | 658.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 18.17 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.other-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.operating-expenses | 166.92 | 141.8 | 147.6 | 115.3 | ||||||
income-statement-row.row.cost-and-expenses | 320.92 | 293.1 | 316.6 | 255.8 | ||||||
income-statement-row.row.interest-income | 28.89 | 27.7 | 2.3 | 30.3 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.total-operating-expenses | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.depreciation-and-amortization | 25.72 | 48.8 | -5.8 | -11 | ||||||
income-statement-row.row.ebitda-caps | -19.96 | - | - | - | ||||||
income-statement-row.row.operating-income | -45.68 | -4.2 | 574.2 | 554.6 | ||||||
income-statement-row.row.income-before-tax | 599.85 | 617.7 | 551.5 | 530.8 | ||||||
income-statement-row.row.income-tax-expense | 759.56 | 756.1 | 60.8 | 61.5 | ||||||
income-statement-row.row.net-income | -131.04 | -119 | 490.7 | 469.3 |
Často kladené otázky
Čo je Maravai LifeSciences Holdings, Inc. (MRVI) celkové aktíva?
Maravai LifeSciences Holdings, Inc. (MRVI) celkové aktíva sú 1487450000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 138320000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.438.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -0.232.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.478.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.167.
Aká je Maravai LifeSciences Holdings, Inc. (MRVI) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -119029000.000.
Aký je celkový dlh firmy?
Celkový dlh je 610967000.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 141799000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 561691000.000.